Communiqués de presse.

Communiqués de presse liés à la thérapie par stimulation des voies aériennes supérieures Inspire™

Inspire Medical’s STAR Clinical Trial Results Published in The New England Journal of Medicine
January 8, 2013

Inspire Medical Systems, Inc., developer of the novel Inspire® Upper Airway Stimulation (UAS) therapy for treating obstructive sleep apnea (OSA), announced today that results from its STAR (Stimulation Therapy for Apnea Reduction) pivotal clinical trial have been published in the January 9 issue of the New England Journal of Medicine.

View Article

Inspire Medical Systems Secures $14.5M in Series C Financing, Completes Implants in its STAR Pivotal Trial, and Announces Publication of Feasibility Study Results
May 11, 2012

Inspire Medical Systems, the leading developer of neurostimulation therapies for the treatment of obstructive sleep apnea (OSA), provided an update today on four important company initiatives:

Read More...

Inspire Medical Systems Reaches Milestones with its Sleep Apnea Therapy
June 9th, 2011

STAR pivotal trial actively recruiting and implanting patients at 9 US sites; Feasibility study data shows therapy may significantly reduce severity of sleep apnea in well selected patients.

Read More...

Inspire Medical Systems annonce l'approbation FDA pour les essais cliniques clés
30 Novembre 2010

Le dispositif Inspire pour l'apnée obstructive du sommeil sera testé sur divers sites aux États-Unis et en Europe.

En lire plus...

Inspire Medical Systems termine les premiers implants du système Inspire II pour le traitement de l'apnée obstructive du sommeil
26 février 2009

La seconde génération d'appareils implantables utilise la stimulation électrique pour éviter l'obstruction des voies aériennes durant le sommeil.

En lire plus...